Photocure ASA

Photocure ASA: Save the date - Hexvix/Cysview update and second quarter 2016 results

Oslo, Norway, 6 July 2016: Photocure ASA will present its second quarter report

on Tuesday 23 August 2016 at Hotel Continental, Norway, and is proud to announce

Dr. Sia Daneshmand as keynote speaker at the event. Dr. Daneshmand will provide

an update on Hexvix/Cysview following the new bladder cancer guidelines from

American Urological Association (AUA) and the Society of Urological Oncology

(SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/

Cysview is recommended.

Agenda (CET)

08:30 - 09:05 Q2 presentation by Kjetil Hestdal, President and

CEO, and Erik Dahl, CFO

09:05 - 09:15 Break

09:15 - 09:45 Dr. Sia Daneshmand, MD, Associate Professor of

Urology (Clinical Scholar); Director of Urologic Oncology, Director of Research

and Fellowship Director, USC Institute of Urology at University of Southern

California, Los Angeles, USA

09:45 - 10:00 Ambaw Bellete, President, Photocure Inc. and Head,

US Commercial Operations

A light snack will be served from 08:00.

The presentations will be live streamed at www.photocure.com. More details will

be provided later.

To attend the presentation, please register by sending an email to

For further information, please contact:

Photocure

Erik Dahl, CFO

Tel: +47 450 55 000, Email: [email protected]

Notes to editors

About Photocure ASA

Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company

and world leader in photodynamic technology. Based on our unique proprietary

Photocure Technology(TM) platform, Photocure develops and commercializes highly

selective and effective solutions within disease areas with high unmet medical

need, such as bladder cancer, HPV and precancerous cervical lesions, colorectal

cancer and skin conditions. Our aim is to provide solutions which can improve

health outcomes for patients worldwide. Photocure is listed on the Oslo Stock

Exchange (OSE: PHO). Information about Photocure is available at

www.photocure.com

This information is subject to the disclosure requirements pursuant to section

5-12 of the Norwegian Securities Trading Act.

[HUG#2025768]

AI Terminal